- Trials with a EudraCT protocol (127)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
127 result(s) found for: Pulmonary edema.
Displaying page 3 of 7.
EudraCT Number: 2007-001670-84 | Sponsor Protocol Number: A 093 | Start Date*: 2007-09-12 | |||||||||||
Sponsor Name:Jassen-Cilag International NV | |||||||||||||
Full Title: Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure | |||||||||||||
Medical condition: Acute Decompensated Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) LT (Completed) DE (Completed) GR (Completed) SE (Completed) NL (Completed) BG (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002803-42 | Sponsor Protocol Number: 15.05.2007 | Start Date*: 2008-03-05 |
Sponsor Name:Univ.Clinic of Internal Medicine II, Department of Cardiology, Medical University of Vienna, Austria | ||
Full Title: Inhaled Iloprost for patients with pulmonary arterial hypertension and right heart failure:a pilot feasibility trial | ||
Medical condition: Pulmonary arterial hypertension (PAH) is associated with poor prognosis.The most common cause of death is right heart failure. The fact that right heart failure is associated with low systemic per... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-001236-10 | Sponsor Protocol Number: COVID-19 | Start Date*: 2020-03-31 |
Sponsor Name:Amsterdam UMC | ||
Full Title: COUNTER-COVID - Oral imatinib to prevent pulmonary vascular leak in Covid19 – a randomized, double --blind, placebo controlled, clinical trial in patients with severe Covid19 disease’ | ||
Medical condition: Covid19 is characterized by hypoxemic respiratory failure, caused by extensive vascular leak and pulmonary edema early in the course of disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-005811-34 | Sponsor Protocol Number: 24d005 | Start Date*: 2018-07-05 |
Sponsor Name:VU Medical Center, Amsterdam | ||
Full Title: Pregnancy reLated Acute hyperTension INtervention Action: a randomized trial comparing labetalol and nicardipine in women with acute hypertension in pregnancy (Platina-trial) | ||
Medical condition: To asses optimal treatment of hypertension of hypertensive disorders in pregnancy | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002669-37 | Sponsor Protocol Number: GB002-2101 | Start Date*: 2020-10-08 | |||||||||||
Sponsor Name:GB002, Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arter... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension (PAH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) AT (Completed) CZ (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001646-18 | Sponsor Protocol Number: AMB115811 | Start Date*: 2013-04-25 | |||||||||||
Sponsor Name:GlaxoSmithKline, S.A. | |||||||||||||
Full Title: A randomised, multicentre, double-blind, placebo-controlled study of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) | |||||||||||||
Medical condition: Subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) AT (Completed) DE (Completed) GB (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014377-40 | Sponsor Protocol Number: Bay 58-2667/14560 | Start Date*: 2010-01-08 | |||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||
Full Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenousl... | |||||||||||||
Medical condition: Acute Decompensated Chronic Congestive Heart Failure (ADHF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) AT (Prematurely Ended) SK (Prematurely Ended) SI (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002403-13 | Sponsor Protocol Number: Ularitide-1502 | Start Date*: 2006-11-20 | |||||||||||
Sponsor Name:PDL BioPharma Inc | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blinded, Placebo-controlled Study of Ularitide in the Treatment of Subjects with Acute Decompensated Heart Failure | |||||||||||||
Medical condition: Acute decompensated heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) LT (Prematurely Ended) AT (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000890-29 | Sponsor Protocol Number: Destro | Start Date*: 2011-03-28 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | |||||||||||||
Full Title: Instrumental and clinical effects of withdrawal of beta blockers therapy in patients with heart failure and right ventricular dysfunction'' | |||||||||||||
Medical condition: heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000780-48 | Sponsor Protocol Number: J3E-MC-EZDB | Start Date*: 2022-11-28 | ||||||||||||||||
Sponsor Name:Eli Lilly and Company | ||||||||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3540378 in Adults with Worsening Chronic Heart Failure with Preserved Ejection Fraction (HF... | ||||||||||||||||||
Medical condition: HFpEF (heart failure with preserved ejection fraction) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003341-15 | Sponsor Protocol Number: FFIS/2019/01/AS | Start Date*: 2022-10-21 | |||||||||||
Sponsor Name:Fundación para la Formación e Investigación Sanitarias de la Región de Murcia (FFIS) | |||||||||||||
Full Title: Aspirin versus placebo in twin pregnancies for preeclampsia prevention: A multicentre, randomised, double-blind, placebo-controlled trial. | |||||||||||||
Medical condition: Pre-eclampsia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) AT (Ongoing) DK (Trial now transitioned) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014378-16 | Sponsor Protocol Number: Bay 58-2667/14663 | Start Date*: 2010-01-14 | |||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||
Full Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of Low Dose BAY 58-2667 (25 μg/h, 10 μg/h) Given Intravenously ... | |||||||||||||
Medical condition: Acute Decompensated Chronic Congestive Heart Failure (ADHF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) IE (Prematurely Ended) AT (Prematurely Ended) FR (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004854-33 | Sponsor Protocol Number: 03-AnIt-14/UKM14_0066 | Start Date*: 2016-02-05 | ||||||||||||||||
Sponsor Name:University Hospital Muenster | ||||||||||||||||||
Full Title: Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH-Trial). | ||||||||||||||||||
Medical condition: Critically ill patients with acute kidney injury | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-001852-36 | Sponsor Protocol Number: CLOROTIC | Start Date*: 2014-01-02 |
Sponsor Name:Sociedad Española de Medicina Interna | ||
Full Title: Randomized, double blinded, multicenter study, to asses Safety and Efficacy of the Combination of Loop With Thiazide-type Diuretics vs Loop diuretics with placebo in Patients With Decompensated Hea... | ||
Medical condition: Security and efficacy of Hidroclorothiazide plus Loop Diuretics in patients with descompensated heart failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001774-23 | Sponsor Protocol Number: 020518-1 | Start Date*: 2018-07-19 |
Sponsor Name:Tampere university hospital | ||
Full Title: Clinical Drug Trial: Efficacy, safety and pharmacokinetics of tinzaparin during Slow Low Efficient Daily Dialysis in Intensive Care Patients | ||
Medical condition: Patients with clinical indication for pharmacological thromboprophylaxis and slow low efficient daily dialysis (SLEDD). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004059-18 | Sponsor Protocol Number: 17909 | Start Date*: 2019-06-27 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A Multicenter, Randomized, Parallel Group, Double Blind, Active and Placebo Controlled Study of BAY 1753011, a Dual V1a/V2 Vasopressin Receptor Antagonist, in Patients with Congestive Heart Failure... | |||||||||||||
Medical condition: Heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PT (Completed) AT (Completed) PL (Completed) GR (Completed) ES (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000756-41 | Sponsor Protocol Number: DEB-EPIV-201 | Start Date*: 2006-04-24 |
Sponsor Name:Debiopharm SA | ||
Full Title: Phase IIa Multicenter 1 Week Treatment, Randomised, Double-Blind, Placebo Controlled Study of Depelestat in Patients Suffering from Acute Respiratory Distress Syndrome | ||
Medical condition: Acute Respiratory Distress Syndrome (ARDS) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-001262-35 | Sponsor Protocol Number: D1690C00078 | Start Date*: 2023-02-09 | |||||||||||
Sponsor Name:The Brigham and Women's Hospital, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients Who Have Been St... | |||||||||||||
Medical condition: The study is evaluating the effect of In-hospital initiation of dapagliflozin in patients who have been stabilized during hospitalization for Acute Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002546-49 | Sponsor Protocol Number: SCP-01-001 | Start Date*: 2014-10-03 |
Sponsor Name:scPharmaceuticals Inc | ||
Full Title: A single center, randomized, open-label, cross-over exploratory study to evaluate the pharmacodynamic and pharmacokinetic response to a subcutaneous administration or oral administration of furosem... | ||
Medical condition: Fluid overload in heart failure | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-000829-37 | Sponsor Protocol Number: NL52341.100.15 | Start Date*: 2015-05-06 |
Sponsor Name:Radboud University Medical Center | ||
Full Title: Fluid hydration to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis: the FLUYT-prevent trial. a multicenter randomized controlled superiority trial. | ||
Medical condition: Patients with choledocholithiasis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
